trending Market Intelligence /marketintelligence/en/news-insights/trending/DvtFot0w3Nr3G5x9q8EvVw2 content esgSubNav
In This List

Spectrum Pharmaceuticals terminates CEO


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Spectrum Pharmaceuticals terminates CEO

The Spectrum Pharmaceuticals Inc. board terminated Rajesh Shrotriya from his position as CEO without cause.

Joseph Turgeon, the company's president and COO, will take over Shrotriya's position, becoming company president and CEO instead.

Turgeon, who will also become a director of the company, has more than three decades of experience in the pharmaceutical industry, including various executive leadership roles at Amgen Inc.

Thomas Riga, who currently serves as executive vice president, chief commercial officer and head of business development, will transition to the post of COO.

Riga has over 15 years of experience in pharmaceutical sales and management from his time at Amgen Inc., Eli Lilly and Co. and Dendreon Pharmaceuticals Inc.

Meanwhile, current director Stuart Krassner was appointed the chairman of Spectrum Pharmaceutical's board.